Sceneray Medical Completes Over RMB 100 Million Series D Financing with China Renaissance as Exclusive Financial Advisor

VCBeat (WeChat ID: vcbeat) has learned that on April 21, SceneRay, a leading Chinese medical device technology company specializing in the research, development, and production of deep brain stimulation systems, announced the completion of its Series D financing round, exceeding RMB 100 million. The round was led by Yanchuang Capital, with participation from Deyi Capital, Taihao Capital, Shanghai Yehao, and other institutions. China Renaissance served as the exclusive financial advisor for this transaction.

The proceeds from this funding round will be primarily allocated to the development of the company’s existing pipeline of Deep Brain Stimulation (DBS) products and clinical trials for new indications, as well as to the marketing and commercialization of its marketed product portfolio. Moving forward, the company remains committed to providing more comprehensive solutions for clinical treatment, thereby better serving the vast number of patients in China with conditions such as Parkinson’s disease.

Founded in 2009, SceneRay has grown over the past decade into an innovative high-tech medical device enterprise integrating R&D, manufacturing, and sales. As a highly influential player in the industry, SceneRay has assembled a elite R&D team by recruiting top talents from Tsinghua University, Peking University, Shanghai Jiao Tong University, Fudan University, and overseas returnees. In response to market dynamics, the company continuously drives technological innovation and product development, having secured more than 200 domestic patents and over 10 international patents to date. In the frontier field of neuroscience, SceneRay has achieved remarkable outcomes leveraging its core technological advantages and independent R&D capabilities, and will continue to empower industry transformation with its leading technologies in the future.

Mr. Ning Yihua, Founder and Chairman of SceneRay, stated, “After more than a decade of relentless dedication, SceneRay has achieved remarkable success. Our independently developed neuromodulation chips have placed China at the forefront of the global landscape, and our brain pacemakers, launched ahead of the market, have received unanimous recognition within the industry. Successfully completing Series D financing during this period of rapid growth will bring infinite possibilities to SceneRay’s development. Finally, we extend our heartfelt gratitude to both new and existing shareholders for their unwavering support. In the future, SceneRay will remain true to its original aspiration: leveraging innovations in technology, clinical applications, and clinical service models to provide healthcare institutions and physicians with more convenient, reliable, and precise medical devices and service solutions. We aim to enable more patients to benefit from advanced medical technologies and establish ourselves as a world-class leading enterprise, showcasing the exceptional strength of Chinese intelligent manufacturing on the international stage through cutting-edge technology.”

Ms. Liu Zeng, President and Partner of Yanchuang Capital, stated, “We are delighted to participate in SceneRay’s current financing round. SceneRay has overcome significant challenges in the field of neuromodulation, establishing a robust foundation in technology, product applications, and ecosystem development. We look forward to seeing the SceneRay team continue to grow and leverage its forward-looking strategic layout and extensive clinical-technical expertise to seize future market opportunities ahead of competitors. Yanchuang Capital will fully support SceneRay in further expanding the clinical applications and solutions for neuromodulation, thereby benefiting more patients.”

Mr. Xie Yijing, Managing Director and Head of the Healthcare and Life Sciences Group at China Renaissance, stated, “China Renaissance is honored to have supported SceneRay through multiple rounds of financing, witnessing the company’s journey in striving for independent innovation and domestic breakthroughs in high-end, cutting-edge technological fields. We believe that the successful completion of this round of financing will empower the company to achieve even greater strides.”

SceneRay, founded in 2009, has grown over the past decade into an innovative high-tech medical device enterprise integrating research and development, manufacturing, and sales. As a highly influential player in the industry, SceneRay has assembled a top-tier R&D team by recruiting outstanding talents from Tsinghua University, Peking University, Shanghai Jiao Tong University, Fudan University, and overseas returnees. The company continuously drives technological innovation and product development in response to market dynamics, having secured more than 200 domestic patents and over 10 international patents to date. In the frontier field of neuroscience, SceneRay has achieved remarkable results leveraging its core technological advantages and independent R&D capabilities, and will continue to empower industry transformation with its leading technologies in the future.

Yanchuang Capital was founded in June 2010 as a high-tech enterprise investment and capital operation platform, jointly established by Peking University alumni and alumni-affiliated enterprises engaged in venture capital and the commercialization of university technological achievements, under the advocacy and support of the Science and Technology Development Department of Peking University. Currently, Yanchuang Capital operates three major business segments: equity investment, securities investment, and cooperation with listed companies including mergers, acquisitions, and restructurings, with assets under management exceeding RMB 6 billion. Among its portfolio companies, those already listed include Jiangfeng Electronics (300666.SH), PIESAT Information Technology (688066.SH), Hotgen Biotech (688068.SH), Ningbo Water Meter (603700.SH), Zeltis Pharma (688266.SH), Ronbay Technology (688005.SH), Quecheng Silica (605183.SH), OLED Material Technologies (688378.SH), and Shentong Technology (605228.SH).

Yanchuang Capital has strategically positioned itself in the biopharmaceutical sector and other areas of the broader healthcare industry. Its portfolio includes not only listed companies such as Hotgen Biotech and Zai Lab, but also numerous renowned innovative drug developers like Yuhang Medicine, Tianjing Hangzhou, Apollomics, Aikobio, Laekna Therapeutics, Jianxin Yuanli, and Mabwell Bioscience.

Founded in 2016, Deyi Capital prioritizes investments in healthcare, information services, consumption upgrading, and other sectors. Its management team boasts extensive experience in investment, investment banking, and industrial operations, along with broad market resources and specialized post-investment service and management capabilities. In the healthcare sector, Deyi Capital has invested in industry-leading and innovative enterprises, including Zeltis Pharma (688266.SH), Allist Pharmaceuticals (688578.SH), Yuli Life Sciences, Keymed Biosciences, InnoCare Pharma, Akebia Therapeutics, Lipin Pharmaceutical, Manteia, Feishuo Biotechnology, and Huamai Taike.

Suzhou Taihao Venture Capital was founded in June 2014, positioning itself as a professional early-stage investment institution with a primary focus on medical devices, the internet, and high-end manufacturing. Since its inception, Taihao Capital has adhered to market-oriented operational principles. On this basis, it has extensively collaborated with emerging industry guidance funds at various levels, including the Suzhou Municipal Science and Technology Bureau, the Development and Reform Commission, Suzhou Industrial Park, and Taicang High-Tech Industrial Development Zone. By fully leveraging the combined resource advantages of state-owned and social capital, Taihao Capital emphasizes the integration of resources across capital, industry, management, and marketing domains during the investment process. This approach safeguards the entrepreneurial journey of portfolio companies and provides precise services. Investment cases include Suzhou SceneRay Medical, Juhe Data (in the IPO tutoring stage), Dikai'er Medical, Shanghai Neumitra Medical, Nanjing Wolfman Medical, Baidao Medical, and Terui Pharmaceutical. Its partners have previously participated in or led the development of listed companies such as MicroPort Scientific Corporation (00853.HK), SVG Optronics (300331.SZ), and Kintor Pharmaceutical Limited (09939.HK).